Resultats de la cerca - Attard, G

Prostate epithelial stem cells per Rizzo, S., Attard, G., Hudson, D. L.

Obtenir text complet Obtenir text complet Obtenir text complet

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects per Ferraldeschi, R, Welti, J, Luo, J, Attard, G, de Bono, JS

Obtenir text complet Obtenir text complet Obtenir text complet

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development per Attard, G, Sarker, D, Reid, A, Molife, R, Parker, C, de Bono, J S

Obtenir text complet Obtenir text complet Obtenir text complet

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail per Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S

Obtenir text complet Obtenir text complet Obtenir text complet

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours per Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M

Obtenir text complet Obtenir text complet Obtenir text complet

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer per Pezaro, C, Mukherji, D, Tunariu, N, Cassidy, A M, Omlin, A, Bianchini, D, Seed, G, Reid, A H M, Olmos, D, de Bono, J S, Attard, G

Obtenir text complet Obtenir text complet Obtenir text complet

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer per Omlin, A, J Pezaro, C, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G

Obtenir text complet Obtenir text complet Obtenir text complet

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer' per Omlin, A, Pezaro, C J, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G

Obtenir text complet Obtenir text complet Obtenir text complet

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone per Salvi, S, Casadio, V, Conteduca, V, Burgio, S L, Menna, C, Bianchi, E, Rossi, L, Carretta, E, Masini, C, Amadori, D, Calistri, D, Attard, G, De Giorgi, U

Obtenir text complet Obtenir text complet Obtenir text complet

The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer per Abdel-Aty, H., O’Shea, L., Amos, C., Brown, L.C., Grist, E., Attard, G., Clarke, N., Cross, W., Parker, C., Parmar, M., Vas As, N., James, N.

Obtenir text complet Obtenir text complet Obtenir text complet

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone per Lorente, D, Omlin, A, Ferraldeschi, R, Pezaro, C, Perez, R, Mateo, J, Altavilla, A, Zafeirou, Z, Tunariu, N, Parker, C, Dearnaley, D, Gillessen, S, de Bono, J, Attard, G

Obtenir text complet Obtenir text complet Obtenir text complet

Visceral disease in castration-resistant prostate cancer per Pezaro, C., Omlin, A., Lorente, D., Rodrigues, D. Nava, Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., Tunariu, N., de Bono, J., Attard, G.

Obtenir text complet Obtenir text complet Obtenir text complet

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement per Foster, C S, Dodson, A R, Ambroisine, L, Fisher, G, Møller, H, Clark, J, Attard, G, De-Bono, J, Scardino, P, Reuter, V E, Cooper, C S, Berney, D M, Cuzick, J

Obtenir text complet Obtenir text complet Obtenir text complet

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone per Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C. J., Petrylak, D. P., Attard, G., Shen, L., Fizazi, K., de Bono, J.

Obtenir text complet Obtenir text complet Obtenir text complet

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer per Attard, G, Clark, J, Ambroisine, L, Fisher, G, Kovacs, G, Flohr, P, Berney, D, Foster, CS, Fletcher, A, Gerald, WL, Moller, H, Reuter, V, De Bono, JS, Scardino, P, Cuzick, J, Cooper, CS

Obtenir text complet Obtenir text complet Obtenir text complet

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer per Attard, G, Clark, J, Ambroisine, L, Mills, I G, Fisher, G, Flohr, P, Reid, A, Edwards, S, Kovacs, G, Berney, D, Foster, C, Massie, C E, Fletcher, A, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S

Obtenir text complet Obtenir text complet Obtenir text complet

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents per Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G

Obtenir text complet Obtenir text complet Obtenir text complet

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer per Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., Sridhar, S. S., Tannock, I. F., de Bono, J. S., Joshua, A. M.

Obtenir text complet Obtenir text complet Obtenir text complet

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can... per Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C

Obtenir text complet Obtenir text complet Obtenir text complet

Transcriptional profiling of primary prostate tumor in metastatic hormone sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAART... per Hamid, A. A., Huang, H-C., Wang, V., Chen, Y-H., Feng, F., Den, R., Attard, G., Van Allen, E. M., Tran, P. T., Spratt, D. E., Dittamore, R., Davicioni, E., Liu, G., DiPaola, R., Carducci, M. A., Sweeney, C. J.

Obtenir text complet Obtenir text complet Obtenir text complet